Experimental antioxidant therapy in ataxia telangiectasia

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 431-436

  Reliene, Ramune ^a,b   Schiestl, Robert H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidants; Ataxia telangiectasia; Atm; Chemoprevention; Lymphoma; Mouse

Indexed keywords

EID: 84861357242     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.4137/cmo.s535     Document Type: Review

References (65)

1. Agarwal, A., Munoz-Najar, U., Klueh, U. et al. 2004. N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am. J. Pathol., 164:1683-96.
2. Albini, A., Morini, M., D'Agostini, F. et al. 2001. Inhibition of angiogenesisdriven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res., 61:8171-8.
3. Barlow, C., Dennery, P.A., Shigenaga, M.K. et al. 1999. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc. Natl. Acad. Sci. U.S.A., 96:9915-9.
4. Barlow, C., Hirotsune, S., Paylor, R. et al. 1996. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell., 86:159-71.
5. Bartkova, J., Horejsi, Z., Koed, K. et al. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434:864-70.
6. Barzilai, A., Rotman, G. and Shiloh, Y. 2002. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst), 1:3-25.
7. Boder, E. 1975. Ataxia-telangiectasia: some historic, clinical and pathologic observations. Birth Defects Orig. Artic. Ser., 11:255-70.
8. Boder, E. 1985. Ataxia-telangiectasia: an overview. Kroc Found Ser., 19:1-63.
9. Boder, E. and Sedgwick, R.P. 1970. Ataxia-telangiectasia. (Clinical and immunological aspects). Psychiatr. Neurol. Med. Psychol. Beih, 13(14):8-16.
10. Borghesani, P.R., Alt, F.W., Bottaro, A. et al. 2000. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc. Natl. Acad. Sci. U.S.A., 97:3336-41.
11. Branca, M., Denurra, T. and Turrini, F. 1988. Reduction of nitroxide free radical by normal and G6PD deficient red blood cells. Free Radic. Biol. Med., 5:7-11.
12. Browne, S.E., Roberts, L.J., Dennery, P.A. et al. 2004. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxiatelangiectasia mice. Free Radic. Biol. Med., 36:938-42.
13. Cohen, M.M., Shaham, M., Dagan, J. et al. 1975. Cytogenetic investigations in families with ataxia-telangiectasia. Cytogenet. Cell. Genet., 15:338-56.
14. Crawford, T.O., Skolasky, R.L., Fernandez, R. et al. 2006. Survival probability in ataxia telangiectasia. Arch. Dis. Child, 91:610-1.
15. Damiani, E., Kalinska, B., Canapa, A. et al. 2000. The effects of nitroxide radicals on oxidative DNA damage. Free Radic. Biol. Med., 28:1257-65.
16. De Flora, S., Izzotti, A., D'Agostini, F. et al. 2001. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis, 22:999-1013.
17. Decramer, M., Rutten-van Molken, M., Dekhuijzen, P.N. et al. 2005. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet, 365:1552-60.
18. Doctrow, S.R., Huffman, K., Marcus, C.B. et al. 2002. Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies. J. Med. Chem., 45:4549-58.
19. Elson, A., Wang, Y., Daugherty, C.J. et al. 1996. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 93:13084-9.
20. Gatti, R.A. 2001. The inherited basis of human radiosensitivity. Acta. Oncol., 40:702-11.
21. Goss, P.E. 1992. New perspectives in the treatment of non-Hodgkin's lymphoma. Semin. Oncol., 19:23-9.
22. Greenstein, S., Ghias, K., Krett, N.L. et al. 2002. Mechanisms of glucocorticoid- mediated apoptosis in hematological malignancies. Clin. Cancer Res., 8:1681-94.
23. Gropp, A. and Flatz, G. 1967. Chromosome breakage and blastic transformation of lymphocytes in ataxia-telangiectasia. Humangenetik, 5:77-9.
24. Gueven, N., Luff, J., Peng, C. et al. 2006. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atmmutant mice with a nitroxide antioxidant. Free Radic. Biol. Med., 41:992-1000.
25. Hahn, S.M., Krishna, C.M., Samuni, A. et al. 1994. Potential use of nitroxides in radiation oncology. Cancer Res., 54:2006s-10s.
26. Ito, K., Takubo, K., Arai, F. et al. 2007. Regulation of reactive oxygen species by Atm is essential for proper response to DNA double-strand breaks in lymphocytes. J. Immunol., 178:103-10.
27. Kamsler, A., Daily, D., Hochman, A. et al. 2001. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res., 61:1849-54.
28. Kawakami, S., Kageyama, Y., Fujii, Y. et al. 2001. Inhibitory effect of N-acetylcysteine on invasion and MMP-9 production of T24 human bladder cancer cells. Anticancer Res., 21:213-9.
29. Keating, M.J., McLaughlin, P. and Cabanillas, F. 1997. Low-grade non- Hodgkin's lymphoma-development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur. J. Cancer Care (Engl), 6:21-6.
30. Kelly, G.S. 1998. Clinical applications of N-acetylcysteine. Altern. Med. Rev., 3:114-27.
31. Krishna, M.C., Grahame, D.A., Samuni, A. et al. 1992. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc. Natl. Acad. Sci. U.S.A., 89:5537-41.
32. Krishna, M.C., Russo, A., Mitchell, J.B. et al. 1996. Do nitroxide antioxidants act as scavengers of O2-. or as SOD mimics? J. Biol. Chem., 271:26026-31.
33. Kuljis, R.O., Xu, Y., Aguila, M.C. et al. 1997. Degeneration of neurons, synapses, and neuropil and glial activation in a murine Atm knockout model of ataxia-telangiectasia. Proc. Natl. Acad. Sci. U.S.A., 94:12688-93.
34. Kuzminov, A. 2001. DNA replication meets genetic exchange: chromosomal damage and its repair by homologous recombination. Proc. Natl. Acad. Sci. U.S.A., 98:8461-8.
35. Lavin, M.F., Birrell, G., Chen, P. et al. 2005. ATM signaling and genomic stability in response to DNA damage. Mutat. Res., 569:123-32.
36. Lavin, M.F., Gueven, N., Bottle, S. et al. 2007. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br. Med. Bull, 81(82):129-47.
37. Lavin, M.F. and Shiloh, Y. 1997. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol., 15:177-202.
38. Lista, F., Bertness, V., Guidos, C.J. et al. 1997. The absolute number of trans-rearrangements between the TCRG and TCRB loci is predictive of lymphoma risk: a severe combined immune deficiency (SCID) murine model. Cancer Res., 57:4408-13.
39. Liyanage, M., Weaver, Z., Barlow, C. et al. 2000. Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood, 96:1940-6.
40. May, J.M., Qu, Z.C., Juliao, S. et al. 2005. Ascorbic acid decreases oxidant stress in endothelial cells caused by the nitroxide tempol. Free Radic. Res., 39:195-202.
41. Melov, S., Doctrow, S.R., Schneider, J.A. et al. 2001. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J. Neurosci., 21:8348-53.
42. Meyn, M.S. 1999. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet., 55:289-304.
43. Mitchell, J.B., Samuni, A., Krishna, M.C. et al. 1990. Biologically active metal-independent superoxide dismutase mimics. Biochemistry, 29:2802-7.
44. Nishikawa, M. and Hashida, M. 2006. Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opin. Drug Deliv, 3:355-69.
45. Prescott, L.F., Park, J., Ballantyne, A. et al. 1977. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet, 2:432-4.
46. Quick, K.L. and Dugan, L.L. 2001. Superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia. Ann. Neurol., 49:627-35.
47. Reichenbach, J., Schubert, R., Schindler, D. et al. 2002. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid. Redox. Signal, 4:465-9.
48. Reichenbach, J., Schubert, R., Schwan, C. et al. 1999. Anti-oxidative capacity in patients with ataxia telangiectasia. Clin. Exp. Immunol., 117:535-9.
49. Reliene, R., Bishop, A.J., Aubrecht, J. et al. 2004a. In vivo DNA deletion assay to detect environmental and genetic predisposition to cancer. Methods Mol. Biol., 262:125-39.
50. Reliene, R., Fischer, E., Schiestl, R.H. and 2004b. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res., 64:5148-53.
51. Reliene, R. and Schiestl, R.H. 2006. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst), 5:852-9.
52. Reliene, R. and Schiestl, R.H. 2007. Antioxidants suppress lymphoma and increase longevity in Atm-deficient mice. J. Nutr., 137:229S-32S.
53. Savitsky, K., Bar-Shira, A., Gilad, S. et al. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science, 268:1749-53.
54. Schubert, R., Erker, L., Barlow, C. et al. 2004. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum. Mol. Genet., 13:1793-802.
55. Shiloh, Y. 2003. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer, 3:155-68.
56. Stumm, M., Neubauer, S., Keindorff, S. et al. 2001. High frequency of spontaneous translocations revealed by FISH in cells from patients with the cancer-prone syndromes ataxia telangiectasia and Nijmegen breakage syndrome. Cytogenet. Cell. Genet., 92:186-91.
57. Taylor, A.M., Metcalfe, J.A., Thick, J. et al. 1996. Leukemia and lymphoma in ataxia telangiectasia. Blood, 87:423-38.
58. Van Schooten, F.J., Besaratinia, A., De Flora, S. et al. 2002. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol. Biomarkers Prev., 11:167-75.
59. Webb, W.R. 1962. Clinical evaluaton of a new mucolytic agent, acetylcysteine. J. Thorac. Cardiovasc. Surg., 44:330-43.
60. Wu, W.S. 2006. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev., 25:695-705.
61. Xu, Y. 1999. ATM in lymphoid development and tumorigenesis. Adv. Immunol., 72:179-89.
62. Xu, Y., Ashley, T., Brainerd, E.E. et al. 1996. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev., 10:2411-22.
63. Yan, M., Kuang, X., Qiang, W. et al. 2002. Prevention of thymic lymphoma development in Atmdddddd/////////mice by dexamethasone. Cancer Res., 62:5153-7.
64. Yan, M., Qiang, W., Liu, N. et al. 2001. The ataxia-telangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes. Faseb J., 15:1132-8.
65. Yi, M., Rosin, M.P. and Anderson, C.K. 1990. Response of fibroblast cultures from ataxia-telangiectasia patients to oxidative stress. Cancer Lett, 54:43-50.